ARTICLE | Finance
4Bio hopes to mix and match next-gen therapies with $150M fund
4Bio Capital is aiming for early stage, highly innovative companies developing ‘advanced therapies’
September 9, 2019 6:01 AM UTC
4Bio Capital is aiming to invest solely in new modalities and treatment paradigms with its new venture fund, including in start-ups that combine more than one novel approach.
The firm has raised $50 million in the first close of 4Bio Ventures II, for which it has set a $150 million target. It will seek to back 8-12 early stage start-ups developing gene and cell therapies, RNA-based therapeutics, targeted therapies and microbiome therapeutics...
BCIQ Company Profiles